ArticleBone marrow transplantation2026
Impact of acute GvHD severity on survival and disease relapse in pediatric patients undergoing allogeneic stem cell transplantation for acute lymphoblastic leukemia: an analysis based on the EBMT-PDWP registry.
Article in Bone marrow transplantation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This retrospective registry-based study investigated the role of acute GvHD in the largest reported pediatric population with acute lymphoblastic leukemia (ALL) undergoing allogeneic stem cell transplantation (HSCT). The study included 3328 children. Median age was 9.6 years (IQR 6-13.9 and range 0.4-18). Forty-nine percent were transplanted from an MSD, 37% from MUD, 14% from MMUD; 68% received a TBI-based conditioning. CSA alone or in combination with methotrexate/MMF was administered as GVHD prophylaxis in 94%. The 100-day cumulative incidence of grade II-IV acute GVHD (aGVHD) was 35% (95% CI: 34-37), while that of grade III-IV was 11% (95% CI: 10-12). Two-year cumulative incidence of chronic GVHD (cGVHD) was 17% (95% CI: 15-18)/extensive cGVHD 8% (95% CI: 7-9). With a median follow-up of 3.1 years, OS, leukemia-free survival (LFS), and GVHD-free/relapse-free survival were 74% (95% CI 72-76), 65% (95% CI 64-67) and 51% (95% CI 49-53), respectively. Using multivariable Cox models in 100-day landmark analysis, any degree of aGVHD was associated with reduced risk of relapse; grade III-IV significantly increased NRM and reduced OS; grade II aGVHD offers the best chances of achieving prolonged LFS (HR = 0.78 (0.64-0.94), p = 0.008). Overall, these data confirm that grade II aGvHD prevents the occurrence of leukaemia relapse without causing unacceptable mortality.
Indexed as
Identifiers
41857187What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.